$8.59
1.84% yesterday
Nasdaq, Dec 24, 07:00 pm CET
ISIN
US31572Q8087
Symbol
FGEN

FibroGen, Inc. Stock price

$8.59
+0.01 0.06% 1M
+3.15 57.81% 6M
-4.65 35.15% YTD
-3.88 31.13% 1Y
-381.67 97.80% 3Y
-1,001.67 99.15% 5Y
-765.42 98.89% 10Y
-541.42 98.44% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.16 1.84%
ISIN
US31572Q8087
Symbol
FGEN
Industry

Key metrics

Basic
Market capitalization
$34.7m
Enterprise Value
$-63.8m
Net debt
positive
Cash
$118.0m
Shares outstanding
4.1m
Valuation (TTM | estimate)
P/E
0.2 | negative
P/S
4.2 | 5.0
EV/Sales
negative | negative
EV/FCF
3.7
P/B
negative
Financial Health
Equity Ratio
-105.2%
Return on Equity
21.1%
ROCE
-121.3%
ROIC
-1,385.1%
Debt/Equity
-1.1
Financials (TTM | estimate)
Revenue
$8.3m | $6.9m
EBITDA
$-121.5m | $-55.5m
EBIT
$-122.6m | $-59.4m
Net Income
$215.7m | $-19.0m
Free Cash Flow
$-17.1m
Growth (TTM | estimate)
Revenue
-95.4% | -76.8%
EBITDA
-34.7% | 56.7%
EBIT
-29.8% | 54.7%
Net Income
277.1% | 60.0%
Free Cash Flow
86.5%
Margin (TTM | estimate)
Gross
345.7%
EBITDA
-1,464.1% | -805.9%
EBIT
-1,477.2%
Net
2,598.9% | -276.3%
Free Cash Flow
-206.0%
More
EPS
$53.3
FCF per Share
$-4.2
Short interest
3.4%
Employees
225
Rev per Employee
$130.0k
Show more

Is FibroGen, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

FibroGen, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a FibroGen, Inc. forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a FibroGen, Inc. forecast:

Buy
75%
Hold
25%

Financial data from FibroGen, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
8.30 8.30
95% 95%
100%
- Direct Costs -20 -20
149% 149%
-246%
29 29
79% 79%
346%
- Selling and Administrative Expenses 7.14 7.14
92% 92%
86%
- Research and Development Expense 18 18
88% 88%
214%
-121 -121
35% 35%
-1,464%
- Depreciation and Amortization 1.09 1.09
74% 74%
13%
EBIT (Operating Income) EBIT -123 -123
30% 30%
-1,477%
Net Profit 216 216
277% 277%
2,598%

In millions USD.

Don't miss a Thing! We will send you all news about FibroGen, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

FibroGen, Inc. Stock News

Neutral
Seeking Alpha
about one month ago
FibroGen, Inc. ( FGEN ) Q3 2025 Earnings Call November 10, 2025 5:00 PM EST Company Participants Thane Wettig - CEO & Director David DeLucia - Senior VP & CFO Conference Call Participants Gaia Vasiliver-Shamis Andy Hsieh Matthew Keller - H.C. Wainwright & Co, LLC, Research Division Chen Lin Presentation Operator Hello, and thank you for standing by.
Neutral
GlobeNewsWire
about 2 months ago
SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce third quarter 2025 financial results on Monday, November 10 after market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
Neutral
GlobeNewsWire
3 months ago
SAN FRANCISCO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the initiation of the Phase 2 monotherapy, dose-optimization trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46-expressing cancer lesions in patients with metastatic castration-resistant prostate cancer (mCRPC). The trial will also assess the diagnostic and pred...
More FibroGen, Inc. News

Company Profile

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.

Head office United States
CEO Thane Wettig
Employees 225
Founded 1993
Website www.fibrogen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today